ALTEOGEN Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-96.0% vs price
Base Case (Median)
-94.1% vs price
Bull Case (75th pct.)
-86.9% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $6034.54 | -98.2% | High (40%) |
| PE Comparable | $46655.37 | -86.2% | Medium (25%) |
| Growth Trajectory DCF | $173607.68 | -48.5% | Medium (20%) |
| Graham Number | $19932.22 | -94.1% | Medium (40%) |
| EV/EBITDA | $19634.54 | -94.2% | Medium (20%) |
| EV/FCF | $41527.58 | -87.7% | Medium (20%) |
| Earnings Power Value | $7117.93 | -97.9% | Medium (50%) |
Based on 7 out of 8 methods, 196170.KQ appears overvalued at the current price of $337000.00. The base case fair value of $19932.22 implies 94.1% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.